Literature DB >> 19145479

Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays.

Evangelos Tsiambas1, Loukas Manaios, Costas Papanikolopoulos, Dimitrios N Rigopoulos, Dimitrios Tsounis, Andreas Karameris, Aspasia Soultati, Antigoni Koliopoulou, Christos Kravvaritis, Theodoros Sergentanis, Efstratios Patsouris, Spyridon Dourakis.   

Abstract

Although Epidermal Growth Factor Receptor (EGFR) overexpression is observed frequently in hepatocellular carcinomas (HCC), specific gene deregulation mechanisms remain unknown. Our aim was to investigate the prognostic significance of the combined protein and gene/chromosome 7 numerical alterations. Using tissue microarray technology, thirty-five (n = 35) paraffin embedded histologically confirmed HCCs were cored and re-embedded in a paraffin block. Immunohistochemistry was performed for the determination of EGFR protein levels and evaluated by the performance of digital image analysis. Chromogenic in situ hybridization was also performed based on the use of EGFR gene and chromosome 7 centromeric probes, respectively. EGFR overexpression was observed in 26/35 (74.2%) cases and was correlated to the grade of the tumors and also to the history of the patients (p = 0.013, p = 0.036, respectively). Numerical alterations regarding gene and chromosome 7 were identified in 4/35 (11.4%) and 12/35 (43.2%) cases associated to the grade of the tumors (p = 0.019, p = 0.001, respectively) and to the survival rate of the patients (p = 0.037, p = 0.001, respectively). EGFR overall expression was also correlated to the gene copies (p = 0.020). EGFR gene numerical alterations -although rare- and also chromosome 7 aneuploidy maybe affect prognosis in HCC patients. To our knowledge this is the first chromogenic in situ hybridization analysis based on tissue microarrays in hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19145479     DOI: 10.1007/s12253-008-9146-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  39 in total

1.  Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.

Authors:  H A Lehr; T W Jacobs; H Yaziji; S J Schnitt; A M Gown
Journal:  Am J Clin Pathol       Date:  2001-06       Impact factor: 2.493

Review 2.  Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Authors:  K Breuhahn; T Longerich; P Schirmacher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 3.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

Authors:  C L Arteaga
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

4.  Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites.

Authors:  S Lee; U Park; Y I Lee
Journal:  Virology       Date:  2001-05-10       Impact factor: 3.616

Review 5.  Molecularly targeted therapy for gastrointestinal cancer.

Authors:  Marcus W Wiedmann; Karel Caca
Journal:  Curr Cancer Drug Targets       Date:  2005-05       Impact factor: 3.428

6.  Malignant transformation and EGFR activation of immortalized mouse liver epithelial cells caused by HBV enhancer-X from a human hepatocellular carcinoma.

Authors:  M Miyaki; C Sato; K Sakai; M Konishi; K Tanaka; M Muraoka; R Kikuchi-Yanoshita; Y Nadaoka; H Kanda; T Kitagawa
Journal:  Int J Cancer       Date:  2000-02-15       Impact factor: 7.396

Review 7.  TP53 and liver carcinogenesis.

Authors:  Frank Staib; S Perwez Hussain; Lorne J Hofseth; Xin W Wang; Curtis C Harris
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

8.  Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth.

Authors:  Woo Sung Moon; Kenneth J Chang; Adhip P N Majumdar; Andrzej S Tarnawski
Journal:  Digestion       Date:  2004-06-16       Impact factor: 3.216

9.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Keith Stuart; Lawrence S Blaszkowsky; Alona Muzikansky; Donald P Reitberg; Jeffrey W Clark; Peter C Enzinger; Pankaj Bhargava; Jeffrey A Meyerhardt; Kerry Horgan; Charles S Fuchs; David P Ryan
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

10.  A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.

Authors:  Tanios Bekaii-Saab; Nita Williams; Christoph Plass; Miguel Villalona Calero; Charis Eng
Journal:  BMC Cancer       Date:  2006-12-06       Impact factor: 4.430

View more
  5 in total

1.  Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.

Authors:  Aloísio Felipe-Silva; Alda Wakamatsu; Cinthya Dos Santos Cirqueira; Venâncio Avancini Ferreira Alves
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

2.  Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.

Authors:  Carsten Hagemann; Steffen Fuchs; Camelia M Monoranu; Pia Herrmann; Janice Smith; Tim Hohmann; Urszula Grabiec; Almuth F Kessler; Faramarz Dehghani; Mario Löhr; Ralf-Ingo Ernestus; Giles H Vince; Ulrike Stein
Journal:  Neuro Oncol       Date:  2013-11-11       Impact factor: 12.300

3.  Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues.

Authors:  Ravat Panvichian; Anchalee Tantiwetrueangdet; Pattana Sornmayura; Surasak Leelaudomlipi
Journal:  Biomed Res Int       Date:  2015-09-07       Impact factor: 3.411

4.  EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study.

Authors:  Vanessa Fátima Bernardes; Frederico Omar Gleber-Netto; Sílvia Ferreira de Sousa; Rafael Malagoli Rocha; Maria Cássia Ferreira de Aguiar
Journal:  BMJ Open       Date:  2013-01-28       Impact factor: 2.692

5.  Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma.

Authors:  Hailong Hu; Dawei Tian; Tao Chen; Ruifa Han; Yan Sun; Changli Wu
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.